Novo Nordisk Q3 Earnings

Adjusted Sales: DKK79.20B (est DKK73.55B) - Adjusted EBIT: DKK31.72B (est DKK28.71B) - Adjusted Net: DKK25.60B (est DKK21.47B) - Adjusted Gross Margin: 82.1% (est 80.3%) - Sees FY Adjusted Sales At CER: -2% To +2% (est -2.35%) - Sees FY Adjusted Operating Profit At CER: -2% To +2% - Ozempic Sales: DKK29.71B (est DKK27.19B) - Wegovy Pill Sales: DKK5.39B (est DKK4.64B) - Wegovy Injectable Sales: DKK20.41B - GLP-1 Diabetes Sales: DKK34.75B - Names La Corte As New CFO